Evidence map›Paper›PMID 38802894›Full record

ArticleAnnals of clinical microbiology and antimicrobials2024

Potential antivirulence activity of sub-inhibitory concentrations of ciprofloxacin against Proteus mirabilis isolates: an in-vitro and in-vivo study.

Mohamed A Elhosseini, Tarek E El-Banna, Fatma I Sonbol, Maisra M El-Bouseary

Abstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Antibacterial Activity of Guttation Droplets fromJournal of fungi (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Fluoroquinolones and Biofilm: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohamed A ElhosseiniDepartment of Microbiology and Immunology, Faculty of Pharmacy, Tanta University, Tanta, Egypt. mohamed131145@pharm.tanta.edu.eg.
Tarek E El-BannaDepartment of Microbiology and Immunology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Fatma I SonbolDepartment of Microbiology and Immunology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Maisra M El-BousearyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Tanta University, Tanta, Egypt. maysra_mohamed@pharm.tanta.edu.eg.ORCID http://orcid.org/0000-0001-6503-0719

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProteus mirabilis is a significant nosocomial pathogen that is frequently associated with a wide range of infections, necessitating heightened attention to mitigate potential health risks. Hence, this study was performed to investigate the impact of sub-minimum inhibitory concentrations (MICs) of ciprofloxacin (CIP) on Proteus mirabilis clinical isolates.

methodsThe sub-MICs of CIP were selected using the growth curve approach. The untreated and treated isolates with sub-MICs of CIP were assessed for their biofilm development, motilities on agar, and other virulence factors. The cell morphology of untreated and treated isolates with sub-MIC of CIP was explored using electron microscope. Moreover, the expression levels of the virulence genes in isolates were measured using quantitative real-time PCR.

resultsData revealed that sub-MICs of CIP significantly (p < 0.05), in a concentration-dependent manner, inhibited biofilm formation and other virulence factors in the selected isolates. Electron microscope analysis showed cell enlargement and various abnormalities in the cell wall and membrane integrity.

conclusionSub-MICs of CIP exhibited inhibition of virulence and alterations in morphological integrity against P. mirabilis isolates.

Indexed as

Anti-Bacterial AgentsBiofilmsCiprofloxacinMicrobial Sensitivity TestsProteus InfectionsProteus mirabilisVirulence FactorsHumansVirulenceAnti-Bacterial AgentsCiprofloxacinVirulence FactorsBiofilmCiprofloxacinProteus mirabilisSub-inhibitory concentrationVirulence

Identifiers

PMID38802894
PMCPMC11131287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.